- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Bracco finalizes buy-back from Merck
The Italian government finalized an agreement that allows Bracco to buy back the 50% of its of stock held by Merck. In the same agreement, Bracco will sell its laboratory business to Merck. The clearance completes contrast media company Bracco’s
The Italian government finalized an agreement that allows Bracco to buy back the 50% of its of stock held by Merck. In the same agreement, Bracco will sell its laboratory business to Merck. The clearance completes contrast media company Braccos buy-back from Merck, and positions the company to expand its business, said Diana Bracco, president and CEO of the Bracco Group.
Pharmaceutical firms Merck of Germany and Bracco of Italy have been partners for 70 years. Merck supplied Bracco with key chemicals used in the production of x-ray contrast media. In the time leading up to the sale, the companies debated whether to split the international imaging business from Bracco. The companies believe the split would make the businesses more efficient and allow them to better compete with other firms in the market (SCAN 4/7/99).
The buy-back allows Bracco to set up a new division at its U.S. headquarters in Princeton, NJ. Bracco Devices Division will promote and market the groups products for medical devices. The first product to be promoted and marketed by BDD in the U.S is Acist, a contrast media injector for cardioangiography. This product will be sold exclusively in the U.S. Dr. Alberto Chierici will head the Bracco Devices Division.
Four Strategies to Address the Tipping Point in Radiology
January 17th 2025In order to flip the script on the impact of the radiology workforce shortage, radiology groups and practices need to make sound investments in technologies and leverage partnerships to mitigate gaps in coverage and maximize workflow efficiencies.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
